Citi raised the firm’s price target on Ideaya Biosciences (IDYA) to $65 from $64 and keeps a Buy rating on the shares. The firm is positive on the shares into the OptimUM-02 readout at the end of March.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences price target raised to $52 from $49 at Wedbush
- IDEAYA Biosciences: Buy Rating on Darovasertib/Crizotinib Ahead of Pivotal OpतimUM-02 Readout and Supported by Strong Cash Runway
- Ideaya Biosciences reports Q4 EPS (94c), consensus (95c)
- Ideaya Biosciences price target raised to $45 from $41 at RBC Capital
- Multiple Shots on Goal in High-Unmet-Need Oncology: IDEAYA’s Diversified Pipeline and Strong Funding Underpin Buy Rating